Cure8 research brief
Thiopurines are still widely used in many countries; knowing which patients are more likely to stop treatment because of toxicity can help guide monitoring and risk discussion. Older age and lower body weight were linked to higher risk in this cohort, which may influence prescribing and follow-up plans.
Adult IBD patients starting or currently on thiopurines, gastroenterologists and IBD clinicians, and clinicians working in resource-limited settings in Latin America.
This study (abstract) reports that among 587 Latin American IBD patients treated with thiopurines at a Chilean tertiary centre, 163 (27.7%) stopped therapy because of adverse events (myelosuppression, hepatitis, pancreatitis, gastrointestinal intolerance).
In multivariable analysis, older age and lower body weight were independent risk factors for thiopurine-related adverse events. Details and context The analysis is retrospective and uses clinical records and weight-based dosing to identify adverse events leading to drug discontinuation.
Reported adverse events include myelosuppression and hepatotoxicity, which typically are monitored with blood tests. Practical takeaways The authors conclude that clinicians should use particular caution when starting thiopurines in older or low-weight patients and monitor for hematologic and hepatic toxicity.
This comes from a single-centre Latin American cohort and reflects real-world resource-limited settings.
This is a retrospective single-centre study (abstract-level summary). Findings are association-based and do not prove causation; applicability may vary across populations. The abstract-level report does not provide TPMT/NUDT15 or therapeutic-drug-monitoring data, which can affect thiopurine toxicity risk.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Thalidomide can help treat refractory pediatric IBD but causes peripheral neuropathy. Knowing a cumulative-dose threshold linked to neuropathy could help clinicians balance benefit and neurotoxicity risk.
Perianal fistula complications are serious and difficult to treat. This study suggests starting anti-TNFα therapy early in pediatric Crohn disease may substantially lower the risk of developing these complications,...
This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.
